APA Alıntı

van de Ven, A. L., Tangutoori, S., Baldwin, P., Qiao, J., Gharagouzloo, C., Seitzer, N., . . . Sridhar, S. (2017). Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation. Mol Cancer Ther.

Chicago Stili Alıntı

van de Ven, Anne L., et al. "Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-deficient Prostate Cancer to Radiation." Mol Cancer Ther 2017.

MLA Alıntı

van de Ven, Anne L., et al. "Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-deficient Prostate Cancer to Radiation." Mol Cancer Ther 2017.